



July 26, 2017

## Five Prime Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8

SOUTH SAN FRANCISCO, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its second quarter 2017 financial results on Tuesday, August 8, 2017, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Tuesday, August 8, 2017, at 4:30 p.m. (ET)/1:30 p.m. (PT) to discuss the company's financial results and provide a general business update.

The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at [www.fiveprime.com](http://www.fiveprime.com). Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 61862496.

The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.

### About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit [www.fiveprime.com](http://www.fiveprime.com).

### CONTACT:

Heather Rowe

Investor Relations

415-365-5737

[heather.rowe@fiveprime.com](mailto:heather.rowe@fiveprime.com)

 Primary Logo

Source: Five Prime Therapeutics, Inc.

News Provided by Acquire Media